Table 2.
Effect of rapamycin on lifespan of various mouse models of human disease
| Mouse strain | Age started | Rapa dose* | Increase in lifespan | Reference |
|---|---|---|---|---|
| Mouse models of cancer | ||||
| Ptet−/− | 1 month | 10 mg/kg/day by gavage | 300% M and F | [42] |
| ApcD716 | 6–14 weeks | 3 and 10 mg/kg/day^ | 140–220% M and F | [33] |
| ApcMin/+ | Not given | 40 mg/kg | 78% M and F | [34] |
| HER-2/neu | 2 months | 1.5 mg/kg s.c.# | 13% F | [40] |
| p53−/− | 2 months | 0.5 mg/kg by gavage@ | 30% M | [39] |
| p53+/− | < 5 months | 1.5 mg/kg in water | 28% M | [37] |
| Rb1+/− | 8–10 weeks | 14 ppm | 14% M–9% F | [43] |
| ApcMin/+ | 50 days | 14 and 42 ppm | 280–440% F | [35] |
| HER-2/neu | 4–5 months | 045 mg/kg s.c.# | 5–7% M and F | [41] |
| p53+/− | 2 months | 14 ppm | 15% M – 17% F | [38] |
| Rag2−/− | 3 months | 14 ppm | 120% M and F | [44] |
| IFN-γ−/− | 5 months | 14 ppm | 34% M and F | [44] |
| Mouse models of diseases other than cancer | ||||
| Lmna−/− | 2 months | 14 ppm and 8 mg/kg i.p. every other day | 23 and 57% M and F | [21] |
| Bmal1−/− | 16 weeks | 0.5 mg/kg in water | 50% M and F | [22] |
| Ndufs4−/− | 20 days | 14 and 378 ppm | 29 and 100% M and F | [24] |
| TK2KI/KI | 15 days | 4 mg/kg in water+ | 60% M and F | [23] |
| BKS-Leprdb | 15 weeks | 14 ppm | 0% M–100% F | [25] |
*Given in diet unless otherwise indicated
^Everolimus given by gavage 5 times a week
#Given 3 times a week for a period of 2 weeks followed by 2-week intervals without rapamycin
@Given 5 days followed by 9-day interval without treatment
+Given to dams at 0.8 mg/kg before weaning